BioCryst Pharmaceuticals, Inc.
NASDAQ:BCRXBiotechnology
+$0.09 today
- Market cap
- $1.88B
- Beta
- 0.56
- P/E (TTM)
- -4.8
- EPS (TTM)
- -$1.89
Volume 2.95M
Average 4.85M
BCRX Property, Plant & Equipment (Net)
Physical long-term assets such as land, buildings, and machinery, net of accumulated depreciation.
BioCryst Pharmaceuticals, Inc.NASDAQ: BCRX
Property, Plant & Equipment (Net) · Q2 FY2026 · quarter ended Jun 2026
Property, plant & equipment (net) rises 8.3% from a year ago
Property, plant & equipment (net) stood at $21.67M at the end of Q2 FY2026, up 8.3% from a year earlier and down 5.7% from the prior quarter. Over 3 fiscal years it compounded at +30.1% a year.
Context
- Property, plant & equipment (net) amounted to 3.9% of total assets at the end of Q2 FY2026, down 0.5 pp from a year earlier.
- Property, plant & equipment (net) increased in 1 of the last 3 fiscal years.
What to watch
Whether property, plant & equipment (net) keeps rising in the next quarterly balance sheet after a +8.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Property, Plant & Equipment (Net) history
USD · from the balance sheet
- Latest · FY2025
- 18.99M USD
- Year-over-year change
- -4.0%
- 4-year CAGR
- +5.7%
| Period | Period end | Property, Plant & Equipment (Net) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 18.99M | -4.0% |
| FY2024 | 2024-12-31 | 19.79M | -5.4% |
| FY2023 | 2023-12-31 | 20.91M | +142.7% |
| FY2022 | 2022-12-31 | 8.62M | -43.3% |
| FY2021 | 2021-12-31 | 15.19M | — |
Property, Plant & Equipment (Net) vs competitors
How BCRX compares with its peers on the latest reported figures
- Peers report in different currencies, so property, plant & equipment (net) is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +8.3% is the highest of 4, against a peer median of -11.3%.
- Property, plant & equipment (net) amounts to 3.9% of total assets for BCRX, versus a peer median of 0.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $113.92M USD | -5.3% | -14.5% | 11.1% | |
| Jun 2026 | $21.67M USD | +8.3% | +30.1% | 3.9% | |
| Sep 2026 | €1.11M EUR | -11.3% | +30.7% | 0.4% | |
| Mar 2026 | $831K USD | -55.4% | -35.6% | 0.3% | |
| Peer median (excluding BCRX) | — | -11.3% | -14.5% | 0.4% | |
Competitors are the stored peer set for BCRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 504.39M | 304.77M | 110.64M | 104.92M | 89.74M |
| Short-term Investments | 3.21M | 119.54M | 278.34M | 216.14M | 185.01M |
| Net Receivables | 29.41M | 50.6M | 56.95M | 79.07M | 106.82M |
| Inventory | 15.79M | 27.53M | 28.68M | 8.09M | 5.4M |
| Other Current Assets | 3.35M | 14.06M | 21.35M | 13.75M | 17.38M |
| Total Current Assets | 566.14M | 516.5M | 495.97M | 421.97M | 404.35M |
| Property, Plant & Equipment (Net) | 15.19M | 8.62M | 20.91M | 19.79M | 18.99M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 6.83M | 18.08M | 0 | 21.72M | 61.16M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 6.81M | 80K | 26.94M | 29.66M |
| Total Non-current Assets | 22.02M | 33.5M | 20.99M | 68.45M | 109.81M |
| Total Assets | 588.15M | 550M | 516.96M | 490.42M | 514.16M |
| Account Payables | 27.81M | 14.36M | 20.89M | 11.64M | 15.83M |
| Short-term Debt | 0 | 0 | 0 | 35.45M | 0 |
| Tax Payables | 2.62M | 410K | 0 | 0 | 0 |
| Deferred Revenue | 1.42M | 1.22M | 0 | 0 | 0 |
| Other Current Liabilities | 52M | 36.46M | 86.59M | 64.66M | 129.69M |
| Total Current Liabilities | 103.72M | 105.51M | 149.99M | 160.38M | 196.07M |
| Long-term Debt | 585.46M | 733.28M | 811.27M | 795.92M | 427.23M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 591.42M | 739.08M | 822.5M | 805.97M | 437.25M |
| Total Liabilities | 695.14M | 844.6M | 972.49M | 966.35M | 633.31M |
| Common Stock | 1.84M | 1.88M | 2.06M | 2.09M | 2.13M |
| Retained Earnings | (1.21B) | (1.45B) | (1.68B) | (1.77B) | (1.51B) |
| Accumulated OCI | 177K | 26K | 1.34M | 921K | 38K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (106.99M) | (294.6M) | (455.53M) | (475.93M) | (119.15M) |
| Total Debt | 593.24M | 741.45M | 825.15M | 841.42M | 438.87M |
| Net Debt | 88.85M | 436.69M | 714.51M | 736.5M | 349.14M |
BioCryst Pharmaceuticals, Inc.
NASDAQ:BCRX
Intrinsic Alpha fair value
Locked
Current Price
$7.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.